ArticleProtein science : a publication of the Protein Society2026
Achieving protease substrate-specific inhibition by mAb dual functional selections.
Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Proteases are promiscuous enzymes acting on multiple substrates. Inhibiting pathogenic proteolysis while sparing physiological ones is essential for the development of effective and safe inhibitors. By engineering β-lactamase and levansucrase as selection and counterselection markers in E. coli periplasm, this study established functional positive and negative selections for the facile discovery of protease inhibitory mAbs rendering substrate specificity. Isolated anti-matrix metalloproteinase (MMP)-14 inhibitory mAbs exhibited nanomolar binding affinities and inhibitory potencies, exclusive selectivity, high proteolysis stability, and substrate-specific (SS) inhibition, that is, blocking MMP-14 mediated proteolysis of pro-tumorigenic syndecan-1 (Sdc-1) while allowing cleavage of anti-inflammatory macrophage chemoattractant protein 3 (MCP-3). Mechanistic studies suggested that the isolated Fabs were active-site competitive inhibitors and their substrate specificity was achieved by recognizing the protease's prime subsites shared with Sdc-1 but distinct to that of MCP-3. Given the pharmaceutical significance of SS inhibition, we envision the dual functional selection can be widely applicable to important protease targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.